(Q33909805)

30 July 2017

1 reference

title

Vaccines for preventing infection with Pseudomonas aeruginosa in people with cystic fibrosis (English)

1 reference

30 July 2017

main subject

Pseudomonas aeruginosa

0 references

cystic fibrosis

0 references

author name string

M T Keogan

series ordinal

1

1 reference

30 July 2017

H K Johansen

series ordinal

2

1 reference

30 July 2017

publication date

1 January 2000

1 reference

Cochrane Database of Systematic Reviews

30 July 2017

published in

1 reference

30 July 2017

issue

2

1 reference

30 July 2017

page(s)

CD001399

1 reference

Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis--three year results

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001399

Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001399

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001399

Early intervention and prevention of lung disease in cystic fibrosis: a European consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001399

Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001399

Reduced IL-10 secretion by CD4+ T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001399

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001399

Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: a 5-year longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001399

Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001399

Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001399

The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 typeNote

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001399

10.1002/14651858.CD001399

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference